Shanghai Junshi Biosciences' (SHA:688180, HKG:1877) net loss attributable to owners for 2025 narrowed year on year to 874.4 million yuan, or 0.87 yuan per share, according to a Hong Kong bourse disclosure on Saturday.
Both the pharmaceutical company's Hong Kong and Shanghai shares fell around 5% during Monday's afternoon trade.
The attributable loss a year earlier was 1.28 billion yuan, or 1.30 yuan per share.
Total operating income climbed 28% to 2.50 billion yuan from 1.95 billion yuan in the prior year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.